Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 4.593
Filtrer
1.
Genes (Basel) ; 15(6)2024 Jun 19.
Article de Anglais | MEDLINE | ID: mdl-38927745

RÉSUMÉ

Brain lipid homeostasis is an absolute requirement for proper functionality of nerve cells and neurological performance. Current evidence demonstrates that lipid alterations are linked to neurodegenerative diseases, especially Alzheimer's disease (AD). The complexity of the brain lipidome and its metabolic regulation has hampered the identification of critical processes associated with the onset and progression of AD. While most experimental studies have focused on the effects of known factors on the development of pathological hallmarks in AD, e.g., amyloid deposition, tau protein and neurofibrillary tangles, neuroinflammation, etc., studies addressing the causative effects of lipid alterations remain largely unexplored. In the present study, we have used a multifactor approach combining diets containing different amounts of polyunsaturated fatty acids (PUFAs), estrogen availabilities, and genetic backgrounds, i.e., wild type (WT) and APP/PS1 (FAD), to analyze the lipid phenotype of the frontal cortex in middle-aged female mice. First, we observed that severe n-3 PUFA deficiency impacts the brain n-3 long-chain PUFA (LCPUFA) composition, yet it was notably mitigated by hepatic de novo synthesis. n-6 LCPUFAs, ether-linked fatty acids, and saturates were also changed by the dietary condition, but the extent of changes was dependent on the genetic background and hormonal condition. Likewise, brain cortex phospholipids were mostly modified by the genotype (FAD>WT) with nuanced effects from dietary treatment. Cholesterol (but not sterol esters) was modified by the genotype (WT>FAD) and dietary condition (higher in DHA-free conditions, especially in WT mice). However, the effects of estrogen treatment were mostly observed in relation to phospholipid remodeling in a genotype-dependent manner. Analyses of lipid-derived variables indicate that nerve cell membrane biophysics were significantly affected by the three factors, with lower membrane microviscosity (higher fluidity) values obtained for FAD animals. In conclusion, our multifactor analyses revealed that the genotype, diet, and estrogen status modulate the lipid phenotype of the frontal cortex, both as independent factors and through their interactions. Altogether, the outcomes point to potential strategies based on dietary and hormonal interventions aimed at stabilizing the brain cortex lipid composition in Alzheimer's disease neuropathology.


Sujet(s)
Maladie d'Alzheimer , Précurseur de la protéine bêta-amyloïde , Modèles animaux de maladie humaine , Oestrogènes , Acides gras omega-3 , Lobe frontal , Maladie d'Alzheimer/métabolisme , Maladie d'Alzheimer/génétique , Maladie d'Alzheimer/traitement médicamenteux , Maladie d'Alzheimer/anatomopathologie , Maladie d'Alzheimer/diétothérapie , Animaux , Acides gras omega-3/métabolisme , Acides gras omega-3/pharmacologie , Souris , Lobe frontal/métabolisme , Lobe frontal/effets des médicaments et des substances chimiques , Lobe frontal/anatomopathologie , Femelle , Précurseur de la protéine bêta-amyloïde/génétique , Précurseur de la protéine bêta-amyloïde/métabolisme , Oestrogènes/métabolisme , Oestrogènes/pharmacologie , Souris transgéniques , Préséniline-1/génétique , Préséniline-1/métabolisme , Métabolisme lipidique/effets des médicaments et des substances chimiques , Humains
2.
Open Biol ; 14(6): 240063, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38864245

RÉSUMÉ

Frontotemporal lobe abnormalities are linked to neuropsychiatric disorders and cognition, but the role of cellular heterogeneity between temporal lobe (TL) and frontal lobe (FL) in the vulnerability to genetic risk factors remains to be elucidated. We integrated single-nucleus transcriptome analysis in 'fresh' human FL and TL with genetic susceptibility, gene dysregulation in neuropsychiatric disease and psychoactive drug response data. We show how intrinsic differences between TL and FL contribute to the vulnerability of specific cell types to both genetic risk factors and psychoactive drugs. Neuronal populations, specifically PVALB neurons, were most highly vulnerable to genetic risk factors for psychiatric disease. These psychiatric disease-associated genes were mostly upregulated in the TL, and dysregulated in the brain of patients with obsessive-compulsive disorder, bipolar disorder and schizophrenia. Among these genes, GRIN2A and SLC12A5, implicated in schizophrenia and bipolar disorder, were significantly upregulated in TL PVALB neurons and in psychiatric disease patients' brain. PVALB neurons from the TL were twofold more vulnerable to psychoactive drugs than to genetic risk factors, showing the influence and specificity of frontotemporal lobe differences on cell vulnerabilities. These studies provide a cell type resolved map of the impact of brain regional differences on cell type vulnerabilities in neuropsychiatric disorders.


Sujet(s)
Lobe frontal , Troubles mentaux , Psychoanaleptiques , Lobe temporal , Humains , Psychoanaleptiques/pharmacologie , Lobe frontal/métabolisme , Lobe frontal/anatomopathologie , Lobe temporal/métabolisme , Lobe temporal/anatomopathologie , Troubles mentaux/génétique , Troubles mentaux/métabolisme , Neurones/métabolisme , Récepteurs du N-méthyl-D-aspartate/métabolisme , Récepteurs du N-méthyl-D-aspartate/génétique , Prédisposition génétique à une maladie , Analyse de profil d'expression de gènes , Transcriptome , Régulation de l'expression des gènes , Schizophrénie/génétique , Schizophrénie/métabolisme , Trouble bipolaire/génétique , Trouble bipolaire/métabolisme
3.
Acta Med Okayama ; 78(3): 227-235, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38902210

RÉSUMÉ

Zolpidem, a non-benzodiazepine hypnotic, is primarily used to treat insomnia. In a previous study, pior treatment with non-benzodiazepine receptor agonists was associated with inflammation. The present study aimed to clarify the association between the effects of zolpidem and inflammation in mice treated with lipopolysaccharide (LPS), a known model of inflammation. We assessed the zolpidem-induced loss of righting reflex (LORR) duration 24 h after LPS treatment in mice. Additionally, the expressions of γ-aminobutyric acid (GABA)A receptor subunit and K+-Cl- cotransporter isoform 2 (KCC2) mRNA in the hippocampus and frontal cortex were examined in LPS-treated mice. Pretreatment with LPS was associated with significantly prolonged duration of zolpidem-induced LORR compared to control mice. This effect was significantly attenuated by administering bicuculline, a GABAA receptor antagonist, or flumazenil, a benzodiazepine receptor antagonist, in LPS-treated mice. Compared to controls, LPS-treated mice showed no significant change in the expression of GABAA receptor subunits in the hippocampus or frontal cortex. Bumetanide, an Na+-K+-2Cl- cotransporter isoform 1 blocker, attenuated the extended duration of zolpidem-induced LORR observed in LPS-treated mice. LPS significantly decreased Kcc2 mRNA expression in the hippocampus and the frontal cortex. These findings suggest that inflammation increases zolpidem-induced LORR, possibly through a reduction in KCC2 expression.


Sujet(s)
Lipopolysaccharides , Pyridines , Récepteurs GABA-A , Réflexe de redressement , Symporteurs , Zolpidem , Animaux , Zolpidem/pharmacologie , Souris , Pyridines/pharmacologie , Mâle , Récepteurs GABA-A/métabolisme , Récepteurs GABA-A/effets des médicaments et des substances chimiques , Symporteurs/génétique , Symporteurs/métabolisme , Réflexe de redressement/effets des médicaments et des substances chimiques , Hippocampe/effets des médicaments et des substances chimiques , Hippocampe/métabolisme , , Hypnotiques et sédatifs/pharmacologie , Inflammation/induit chimiquement , Lobe frontal/effets des médicaments et des substances chimiques , Lobe frontal/métabolisme
4.
Brain ; 147(6): 2214-2229, 2024 Jun 03.
Article de Anglais | MEDLINE | ID: mdl-38802114

RÉSUMÉ

Mild traumatic brain injury (mTBI) has emerged as a potential risk factor for the development of neurodegenerative conditions such as Alzheimer's disease and chronic traumatic encephalopathy. Blast mTBI, caused by exposure to a pressure wave from an explosion, is predominantly experienced by military personnel and has increased in prevalence and severity in recent decades. Yet the underlying pathology of blast mTBI is largely unknown. We examined the expression and localization of AQP4 in human post-mortem frontal cortex and observed distinct laminar differences in AQP4 expression following blast exposure. We also observed similar laminar changes in AQP4 expression and localization and delayed impairment of glymphatic function that emerged 28 days following blast injury in a mouse model of repetitive blast mTBI. In a cohort of veterans with blast mTBI, we observed that blast exposure was associated with an increased burden of frontal cortical MRI-visible perivascular spaces, a putative neuroimaging marker of glymphatic perivascular dysfunction. These findings suggest that changes in AQP4 and delayed glymphatic impairment following blast injury may render the post-traumatic brain vulnerable to post-concussive symptoms and chronic neurodegeneration.


Sujet(s)
Aquaporine-4 , Traumatismes par explosion , Système glymphatique , Adulte , Sujet âgé , Animaux , Femelle , Humains , Mâle , Souris , Adulte d'âge moyen , Aquaporine-4/métabolisme , Traumatismes par explosion/complications , Traumatismes par explosion/anatomopathologie , Traumatismes par explosion/métabolisme , Commotion de l'encéphale/métabolisme , Commotion de l'encéphale/complications , Commotion de l'encéphale/anatomopathologie , Commotion de l'encéphale/physiopathologie , Lésions traumatiques de l'encéphale/métabolisme , Lésions traumatiques de l'encéphale/complications , Lésions traumatiques de l'encéphale/anatomopathologie , Lobe frontal/métabolisme , Lobe frontal/anatomopathologie , Lobe frontal/imagerie diagnostique , Système glymphatique/métabolisme , Système glymphatique/anatomopathologie , Imagerie par résonance magnétique , Souris de lignée C57BL , Anciens combattants
5.
Ann Clin Transl Neurol ; 11(6): 1420-1429, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38717724

RÉSUMÉ

OBJECTIVE: Mitochondrial impairments have been implicated in the pathogenesis of Fragile X-associated tremor/ataxia syndrome (FXTAS) based on analysis of mitochondria in peripheral tissues and cultured cells. We sought to assess whether mitochondrial abnormalities present in postmortem brain tissues of patients with FXTAS are also present in plasma neuron-derived extracellular vesicles (NDEVs) from living carriers of fragile X messenger ribonucleoprotein1 (FMR1) gene premutations at an early asymptomatic stage of the disease continuum. METHODS: We utilized postmortem frozen cerebellar and frontal cortex samples from a cohort of eight patients with FXTAS and nine controls and measured the quantity and activity of the mitochondrial proteins complex IV and complex V. In addition, we evaluated the same measures in isolated plasma NDEVs by selective immunoaffinity capture targeting L1CAM from a separate cohort of eight FMR1 premutation carriers and four age-matched controls. RESULTS: Lower complex IV and V quantity and activity were observed in the cerebellum of FXTAS patients compared to controls, without any differences in total mitochondrial content. No patient-control differences were observed in the frontal cortex. In NDEVs, FMR1 premutation carriers compared to controls had lower activity of Complex IV and Complex V, but higher Complex V quantity. INTERPRETATION: Quantitative and functional abnormalities in mitochondrial electron transport chain complexes IV and V seen in the cerebellum of patients with FXTAS are also manifest in plasma NDEVs of FMR1 premutation carriers. Plasma NDEVs may provide further insights into mitochondrial pathologies in this syndrome and could potentially lead to the development of biomarkers for predicting symptomatic FXTAS among premutation carriers and disease monitoring.


Sujet(s)
Ataxie , Vésicules extracellulaires , Protéine du syndrome X fragile , Syndrome du chromosome X fragile , Mitochondries , Tremblement , Humains , Syndrome du chromosome X fragile/génétique , Syndrome du chromosome X fragile/métabolisme , Syndrome du chromosome X fragile/anatomopathologie , Syndrome du chromosome X fragile/physiopathologie , Tremblement/génétique , Tremblement/métabolisme , Tremblement/physiopathologie , Tremblement/anatomopathologie , Vésicules extracellulaires/métabolisme , Ataxie/génétique , Ataxie/métabolisme , Ataxie/anatomopathologie , Ataxie/physiopathologie , Mâle , Sujet âgé , Femelle , Protéine du syndrome X fragile/génétique , Protéine du syndrome X fragile/métabolisme , Adulte d'âge moyen , Mitochondries/métabolisme , Mitochondries/anatomopathologie , Cervelet/métabolisme , Cervelet/anatomopathologie , Sujet âgé de 80 ans ou plus , Encéphale/métabolisme , Encéphale/anatomopathologie , Lobe frontal/métabolisme , Lobe frontal/anatomopathologie
6.
Acta Neuropathol ; 147(1): 91, 2024 05 21.
Article de Anglais | MEDLINE | ID: mdl-38772917

RÉSUMÉ

APOEε4 is the major genetic risk factor for sporadic Alzheimer's disease (AD). Although APOEε4 is known to promote Aß pathology, recent data also support an effect of APOE polymorphism on phosphorylated Tau (pTau) pathology. To elucidate these potential effects, the pTau interactome was analyzed across APOE genotypes in the frontal cortex of 10 advanced AD cases (n = 5 APOEε3/ε3 and n = 5 APOEε4/ε4), using a combination of anti-pTau pS396/pS404 (PHF1) immunoprecipitation (IP) and mass spectrometry (MS). This proteomic approach was complemented by an analysis of anti-pTau PHF1 and anti-Aß 4G8 immunohistochemistry, performed in the frontal cortex of 21 advanced AD cases (n = 11 APOEε3/ε3 and n = 10 APOEε4/ε4). Our dataset includes 1130 and 1330 proteins enriched in IPPHF1 samples from APOEε3/ε3 and APOEε4/ε4 groups (fold change ≥ 1.50, IPPHF1 vs IPIgG ctrl). We identified 80 and 68 proteins as probable pTau interactors in APOEε3/ε3 and APOEε4/ε4 groups, respectively (SAINT score ≥ 0.80; false discovery rate (FDR) ≤ 5%). A total of 47/80 proteins were identified as more likely to interact with pTau in APOEε3/ε3 vs APOEε4/ε4 cases. Functional enrichment analyses showed that they were significantly associated with the nucleoplasm compartment and involved in RNA processing. In contrast, 35/68 proteins were identified as more likely to interact with pTau in APOEε4/ε4 vs APOEε3/ε3 cases. They were significantly associated with the synaptic compartment and involved in cellular transport. A characterization of Tau pathology in the frontal cortex showed a higher density of plaque-associated neuritic crowns, made of dystrophic axons and synapses, in APOEε4 carriers. Cerebral amyloid angiopathy was more frequent and severe in APOEε4/ε4 cases. Our study supports an influence of APOE genotype on pTau-subcellular location in AD. These results suggest a facilitation of pTau progression to Aß-affected brain regions in APOEε4 carriers, paving the way to the identification of new therapeutic targets.


Sujet(s)
Maladie d'Alzheimer , Apolipoprotéine E4 , Protéines tau , Sujet âgé , Sujet âgé de 80 ans ou plus , Femelle , Humains , Mâle , Adulte d'âge moyen , Maladie d'Alzheimer/métabolisme , Maladie d'Alzheimer/génétique , Maladie d'Alzheimer/anatomopathologie , Apolipoprotéine E4/génétique , Apolipoprotéine E4/métabolisme , Lobe frontal/métabolisme , Lobe frontal/anatomopathologie , Génotype , Phosphorylation , Protéomique , Protéines tau/métabolisme , Protéines tau/génétique
7.
PLoS One ; 19(5): e0301267, 2024.
Article de Anglais | MEDLINE | ID: mdl-38753768

RÉSUMÉ

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal neurodegenerative diseases for which at present no cure is available. Despite the extensive research the progress from diagnosis to prognosis in ALS and frontotemporal dementia (FTD) has been slow which represents suboptimal understanding of disease pathophysiological processes. In recent studies, several genes have been associated with the ALS and FTD diseases such as SOD1, TDP43, and TBK1, whereas the hexanucleotide GGGGCC repeat expansion (HRE) in C9orf72 gene is a most frequent cause of ALS and FTD, that has changed the understanding of these diseases. METHODS: The goal of this study was to identify and spatially determine differential gene expression signature differences between cerebellum and frontal cortex in C9orf72-associated ALS (C9-ALS), to study the network properties of these differentially expressed genes, and to identify miRNAs targeting the common differentially expressed genes in both the tissues. This study thus highlights underlying differential cell susceptibilities to the disease mechanisms in C9-ALS and suggesting therapeutic target selection in C9-ALS. RESULTS: In this manuscript, we have identified that the genes involved in neuron development, protein localization and transcription are mostly enriched in cerebellum of C9-ALS patients, while the UPR-related genes are enriched in the frontal cortex. Of note, UPR pathway genes were mostly dysregulated both in the C9-ALS cerebellum and frontal cortex. Overall, the data presented here show that defects in normal RNA processing and the UPR pathway are the pathological hallmarks of C9-ALS. Interestingly, the cerebellum showed more strong transcriptome changes than the frontal cortex. CONCLUSION: Interestingly, the cerebellum region showed more significant transcriptomic changes as compared to the frontal cortex region suggesting its active participation in the disease process. This nuanced understanding may offer valuable insights for the development of targeted therapeutic strategies aimed at mitigating disease progression in C9-ALS.


Sujet(s)
Sclérose latérale amyotrophique , Cervelet , Lobe frontal , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Sclérose latérale amyotrophique/génétique , Sclérose latérale amyotrophique/anatomopathologie , Sclérose latérale amyotrophique/métabolisme , Protéine C9orf72/génétique , Protéine C9orf72/métabolisme , Cervelet/métabolisme , Cervelet/anatomopathologie , Lobe frontal/métabolisme , Lobe frontal/anatomopathologie , Démence frontotemporale/génétique , Démence frontotemporale/anatomopathologie , Démence frontotemporale/métabolisme , microARN/génétique , microARN/métabolisme
8.
J Am Soc Mass Spectrom ; 35(6): 1310-1319, 2024 Jun 05.
Article de Anglais | MEDLINE | ID: mdl-38780475

RÉSUMÉ

The accumulation of amyloid beta (Aß1-42) results in neurotoxicity and is strongly related to neurodegenerative disorders, especially Alzheimer's disease (AD), but the underlying molecular mechanism is still poorly understood. Therefore, there is an urgent need for researchers to discover the proteins that interact with Aß1-42 to determine the molecular basis. Previously, we developed peptide-ligand-induced changes in the abundance of proTeinS (PACTS)-assisted thermal proteome profiling (TPP) to identify proteins that interact with peptide ligands. In the present study, we applied this technique to analyze clinical samples to identify Aß1-42-interacting proteins. We detected 115 proteins that interact with Aß1-42 in human frontal lobe tissue. Pathway enrichment analysis revealed that the differentially expressed proteins were involved mainly in neurodegenerative diseases. Further orthogonal validation revealed that Aß1-42 interacted with the AD-associated protein mitogen-activated protein kinase 3 (MAPK3), and knockdown of the Aß1-42 amyloid precursor protein (APP) inhibited the MAPK signaling pathway, suggesting potential functional roles for Aß1-42 in interacting with MAPK3. Overall, this study demonstrated the application of the PACTS-TPP in clinical samples and provided a valuable data source for research on neurodegenerative diseases.


Sujet(s)
Maladie d'Alzheimer , Peptides bêta-amyloïdes , Fragments peptidiques , Protéomique , Humains , Peptides bêta-amyloïdes/métabolisme , Peptides bêta-amyloïdes/composition chimique , Fragments peptidiques/composition chimique , Fragments peptidiques/métabolisme , Fragments peptidiques/analyse , Protéomique/méthodes , Maladie d'Alzheimer/métabolisme , Protéome/analyse , Protéome/métabolisme , Lobe frontal/métabolisme , Lobe frontal/composition chimique , Précurseur de la protéine bêta-amyloïde/métabolisme , Précurseur de la protéine bêta-amyloïde/composition chimique , Liaison aux protéines
9.
Food Funct ; 15(10): 5579-5595, 2024 May 20.
Article de Anglais | MEDLINE | ID: mdl-38713055

RÉSUMÉ

Attention-deficit/hyperactivity disorder (ADHD) is a developmental disorder and dopaminergic dysfunction in the prefrontal cortex (PFC) may play a role. Our previous research indicated that theobromine (TB), a methylxanthine, enhances cognitive function in rodents via the PFC. This study investigates TB's effects on hyperactivity and cognitive function in stroke-prone spontaneously hypertensive rats (SHR), an ADHD animal model. Male SHRs (6-week old) received a diet containing 0.05% TB for 40 days, while control rats received normal diets. Age-matched male Wistar-Kyoto rats (WKY) served as genetic controls. During the TB administration period, we conducted open-field tests and Y-maze tasks to evaluate hyperactivity and cognitive function, then assessed dopamine concentrations and tyrosine hydroxylase (TH), dopamine receptor D1-5 (DRD1-5), dopamine transporter (DAT), vesicular monoamine transporter-2 (VMAT-2), synaptosome-associated protein-25 (SNAP-25), and brain-derived neurotrophic factor (BDNF) expressions in the PFC. Additionally, the binding affinity of TB for the adenosine receptors (ARs) was evaluated. Compared to WKY, SHR exhibited hyperactivity, inattention and working memory deficits. However, chronic TB administration significantly improved these ADHD-like behaviors in SHR. TB administration also normalized dopamine concentrations and expression levels of TH, DRD2, DRD4, SNAP-25, and BDNF in the PFC of SHR. No changes were observed in DRD1, DRD3, DRD5, DAT, and VMAT-2 expression between SHR and WKY rats, and TB intake had minimal effects. TB was found to have affinity binding to ARs. These results indicate that long-term TB supplementation mitigates hyperactivity, inattention and cognitive deficits in SHR by modulating dopaminergic nervous function and BDNF levels in the PFC, representing a potential adjunctive treatment for ADHD.


Sujet(s)
Trouble déficitaire de l'attention avec hyperactivité , Dopamine , Mémoire à court terme , Rats de lignée SHR , Rats de lignée WKY , Théobromine , Animaux , Mâle , Rats , Théobromine/pharmacologie , Trouble déficitaire de l'attention avec hyperactivité/traitement médicamenteux , Trouble déficitaire de l'attention avec hyperactivité/métabolisme , Mémoire à court terme/effets des médicaments et des substances chimiques , Dopamine/métabolisme , Facteur neurotrophique dérivé du cerveau/métabolisme , Facteur neurotrophique dérivé du cerveau/génétique , Transporteurs de la dopamine/métabolisme , Transporteurs de la dopamine/génétique , Lobe frontal/métabolisme , Lobe frontal/effets des médicaments et des substances chimiques , Cortex préfrontal/métabolisme , Cortex préfrontal/effets des médicaments et des substances chimiques , Tyrosine 3-monooxygenase/métabolisme , Tyrosine 3-monooxygenase/génétique , Modèles animaux de maladie humaine , Protéine SNAP-25/métabolisme
10.
Elife ; 122024 Apr 22.
Article de Anglais | MEDLINE | ID: mdl-38648100

RÉSUMÉ

Genome-wide association studies have revealed >270 loci associated with schizophrenia risk, yet these genetic factors do not seem to be sufficient to fully explain the molecular determinants behind this psychiatric condition. Epigenetic marks such as post-translational histone modifications remain largely plastic during development and adulthood, allowing a dynamic impact of environmental factors, including antipsychotic medications, on access to genes and regulatory elements. However, few studies so far have profiled cell-specific genome-wide histone modifications in postmortem brain samples from schizophrenia subjects, or the effect of antipsychotic treatment on such epigenetic marks. Here, we conducted ChIP-seq analyses focusing on histone marks indicative of active enhancers (H3K27ac) and active promoters (H3K4me3), alongside RNA-seq, using frontal cortex samples from antipsychotic-free (AF) and antipsychotic-treated (AT) individuals with schizophrenia, as well as individually matched controls (n=58). Schizophrenia subjects exhibited thousands of neuronal and non-neuronal epigenetic differences at regions that included several susceptibility genetic loci, such as NRG1, DISC1, and DRD3. By analyzing the AF and AT cohorts separately, we identified schizophrenia-associated alterations in specific transcription factors, their regulatees, and epigenomic and transcriptomic features that were reversed by antipsychotic treatment; as well as those that represented a consequence of antipsychotic medication rather than a hallmark of schizophrenia in postmortem human brain samples. Notably, we also found that the effect of age on epigenomic landscapes was more pronounced in frontal cortex of AT-schizophrenics, as compared to AF-schizophrenics and controls. Together, these data provide important evidence of epigenetic alterations in the frontal cortex of individuals with schizophrenia, and remark for the first time on the impact of age and antipsychotic treatment on chromatin organization.


Sujet(s)
Neuroleptiques , Épigenèse génétique , Lobe frontal , Schizophrénie , Humains , Schizophrénie/génétique , Schizophrénie/traitement médicamenteux , Schizophrénie/métabolisme , Neuroleptiques/pharmacologie , Neuroleptiques/usage thérapeutique , Lobe frontal/métabolisme , Lobe frontal/effets des médicaments et des substances chimiques , Mâle , Femelle , Adulte d'âge moyen , Adulte , Épigénomique , Sujet âgé , Histone/métabolisme
11.
J Neuropathol Exp Neurol ; 83(5): 345-356, 2024 Apr 19.
Article de Anglais | MEDLINE | ID: mdl-38441171

RÉSUMÉ

Identification of central nervous system injury is a critical part of perinatal autopsies; however, injury is not always easily identifiable due to autolysis and immaturity of the developing brain. Here, the role of immunohistochemical stains in the identification of perinatal brain injury was investigated. Blinded semiquantitative scoring of injury was performed on sections of frontal lobe from 76 cases (51 liveborn and 25 stillborn) using H&E, GFAP, Iba-1, and ß-APP stains. Digital image analysis was used to quantify GFAP and Iba-1 staining. Commonly observed pathologies included diffuse white matter gliosis (DWMG) and white matter necrosis (WMN). DWMG scores were very similar on H&E and GFAP stains for liveborn subjects. For stillborn subjects, DWMG scores were significantly higher on GFAP stain than H&E. ß-APP was needed for identification of WMN in 71.4% of stillborn subjects compared to 15.4% of liveborn subjects. Diffuse staining for Iba-1 within cortex and white matter was positively correlated with subject age. Staining quantification on digital image analysis was highly correlated to semiquantitative scoring. Overall, GFAP and ß-APP stains were most helpful in identifying white matter injury not seen on H&E in stillborn subjects. Immunostains may therefore be warranted as an integral part of stillborn brain autopsies.


Sujet(s)
Lésions encéphaliques , Substance blanche , Grossesse , Femelle , Humains , Encéphale/anatomopathologie , Lésions encéphaliques/anatomopathologie , Substance blanche/anatomopathologie , Lobe frontal/métabolisme , Cortex cérébral/anatomopathologie , Protéine gliofibrillaire acide/métabolisme
12.
Nature ; 628(8008): 648-656, 2024 Apr.
Article de Anglais | MEDLINE | ID: mdl-38538789

RÉSUMÉ

Dynamically organized chromatin complexes often involve multiplex chromatin interactions and sometimes chromatin-associated RNA1-3. Chromatin complex compositions change during cellular differentiation and ageing, and are expected to be highly heterogeneous among terminally differentiated single cells4-7. Here we introduce the multinucleic acid interaction mapping in single cells (MUSIC) technique for concurrent profiling of multiplex chromatin interactions, gene expression and RNA-chromatin associations within individual nuclei. When applied to 14 human frontal cortex samples from older donors, MUSIC delineated diverse cortical cell types and states. We observed that nuclei exhibiting fewer short-range chromatin interactions were correlated with both an 'older' transcriptomic signature and Alzheimer's disease pathology. Furthermore, the cell type exhibiting chromatin contacts between cis expression quantitative trait loci and a promoter tends to be that in which these cis expression quantitative trait loci specifically affect the expression of their target gene. In addition, female cortical cells exhibit highly heterogeneous interactions between XIST non-coding RNA and chromosome X, along with diverse spatial organizations of the X chromosomes. MUSIC presents a potent tool for exploration of chromatin architecture and transcription at cellular resolution in complex tissues.


Sujet(s)
Vieillissement , Noyau de la cellule , Chromatine , Lobe frontal , ARN , Analyse sur cellule unique , Sujet âgé , Femelle , Humains , Mâle , Vieillissement/génétique , Maladie d'Alzheimer/génétique , Maladie d'Alzheimer/anatomopathologie , Noyau de la cellule/génétique , Vieillissement de la cellule/génétique , Chromatine/génétique , Chromatine/métabolisme , Chromosomes X humains/génétique , Chromosomes X humains/métabolisme , Lobe frontal/métabolisme , Analyse de profil d'expression de gènes/méthodes , Régions promotrices (génétique) , Locus de caractère quantitatif , ARN/génétique , ARN/métabolisme , ARN long non codant/génétique , ARN long non codant/métabolisme , Analyse sur cellule unique/méthodes , Transcription génétique
13.
Neurochem Int ; 175: 105719, 2024 May.
Article de Anglais | MEDLINE | ID: mdl-38452814

RÉSUMÉ

Cortical synaptic loss has emerged as an early abnormality in Alzheimer's disease (AD) with a strong relationship to cognitive performance. However, the status of synapses in frontotemporal lobar degeneration (FTLD) has received meager experimental attention. The purpose of this study was to investigate changes in cortical synaptic proteins in FTLD with tar DNA binding protein-43 (TDP-43) proteinopathy. A second aim was to study phagocytosis of synaptic proteins by microglia as a surrogate for synaptic pruning. Western blot analysis in frozen tissue from the middle frontal gyrus revealed decreased levels of the presynaptic protein synaptophysin, but slightly increased levels of the postsynaptic density protein 95 (PSD95) in FTLD-TDP. Levels of the dendritic spine protein spinophilin displayed the largest decrease. Double immunofluorescent staining visualized aggregate or punctate synaptic protein immunoreactivity in microglia. Overall, the proportion of microglia containing synaptic proteins was larger in FTLD-TDP when compared with normal controls. The increase in PSD95 levels may represent reactive upregulation of this protein, as suggested in AD. While greater numbers of microglia containing synaptic proteins is consistent with loss of synapses in FTLD-TDP, it may also be an indication of abnormal synaptic pruning by microglia.


Sujet(s)
Maladie d'Alzheimer , Démence frontotemporale , Dégénérescence lobaire frontotemporale , Protéinopathies TDP-43 , Humains , Microglie/métabolisme , Dégénérescence lobaire frontotemporale/génétique , Dégénérescence lobaire frontotemporale/métabolisme , Protéinopathies TDP-43/génétique , Lobe frontal/métabolisme
14.
Neurotherapeutics ; 21(1): e00300, 2024 Jan.
Article de Anglais | MEDLINE | ID: mdl-38241165

RÉSUMÉ

Neurodevelopmental disorders (NDs) are neuropsychiatric conditions affecting central nervous system development, characterized by cognitive and behavioural alterations. Inflammation has been recently linked to NDs. Animal models are essential for understanding their pathophysiology and identifying therapeutic targets. Double-hit models can reproduce neurodevelopmental and neuroinflammatory impairments. Sixty-seven newborn rats were assigned to four groups: Control, Maternal deprivation (MD, 24-h-deprivation), Isolation (Iso, 5 weeks), and Maternal deprivation â€‹+ â€‹Isolation (MD â€‹+ â€‹Iso, also known as double-hit). Cognitive dysfunction was assessed using behavioural tests. Inflammasome, MAPKs, and TLRs inflammatory elements expression in the frontal cortex (FC) and hippocampus (HP) was analysed through western blot and qRT-PCR. Oxidative/nitrosative (O/N) evaluation and corticosterone levels were measured in plasma samples. Double-hit group was affected in executive and working memory. Most inflammasomes and TLRs inflammatory responses were increased in FC compared to the control group, whilst MAPKs were downregulated. Conversely, hippocampal inflammasome and inflammatory components were reduced after the double-hit exposure, while MAPKs were elevated. Our findings reveal differential regulation of innate immune system components in FC and HP in the double-hit group. Further investigations on MAPKs are necessary to understand their role in regulating HP neuroinflammatory status, potentially linking our MAPKs results to cognitive impairments through their proliferative and anti-inflammatory activity.


Sujet(s)
Lobe frontal , Inflammasomes , Rats , Animaux , Inflammasomes/métabolisme , Lobe frontal/métabolisme , Anti-inflammatoires/métabolisme , Système immunitaire/métabolisme , Hippocampe/métabolisme
15.
Psychiatry Res ; 331: 115656, 2024 Jan.
Article de Anglais | MEDLINE | ID: mdl-38071879

RÉSUMÉ

We identified a sub-group (25%) of people with schizophrenia (muscarinic receptor deficit schizophrenia (MRDS)) that are characterised because of markedly lower levels of cortical muscarinic M1 receptors (CHRM1) compared to most people with the disorder (non-MRDS). Notably, bioinformatic analyses of our cortical gene expression data shows a disturbance in the homeostasis of a biochemical pathway that regulates levels of CHRM1. A step in this pathway is the processing of ß-amyloid precursor protein (APP) and therefore we postulated there would be altered levels of APP in the frontal cortex from people with MRDS. Here we measure levels of CHRM1 using [3H]pirenzepine binding, soluble APP (sAPP) using Western blotting and amyloid beta peptides (Aß1-40 and Aß1-42) using ELISA in the frontal cortex (Brodmann's area 6: BA 6; MRDS = 14, non-MRDS = 14, controls = 14). We confirmed the MRDS cohort in this study had the expected low levels of [3H]pirenzepine binding. In addition, we showed that people with schizophrenia, independent of their sub-group status, had lower levels of sAPP compared to controls but did not have altered levels of Aß1-40 or Aß1-42. In conclusion, whilst changes in sAPP are not restricted to MRDS our data could indicate a role of APP, which is important in axonal and synaptic pruning, in the molecular pathology of the syndrome of schizophrenia.


Sujet(s)
Précurseur de la protéine bêta-amyloïde , Schizophrénie , Humains , Précurseur de la protéine bêta-amyloïde/métabolisme , Pirenzépine/métabolisme , Peptides bêta-amyloïdes , Schizophrénie/génétique , Lobe frontal/métabolisme , Récepteur muscarinique de type M1/génétique
16.
Alzheimers Dement ; 20(2): 1156-1165, 2024 Feb.
Article de Anglais | MEDLINE | ID: mdl-37908186

RÉSUMÉ

INTRODUCTION: We assessed TAR DNA-binding protein 43 (TDP-43) seeding activity and aggregates detection in olfactory mucosa of patients with frontotemporal lobar degeneration with TDP-43-immunoreactive pathology (FTLD-TDP) by TDP-43 seeding amplification assay (TDP43-SAA) and immunocytochemical analysis. METHODS: The TDP43-SAA was optimized using frontal cortex samples from 16 post mortem cases with FTLD-TDP, FTLD with tau inclusions, and controls. Subsequently, olfactory mucosa samples were collected from 17 patients with FTLD-TDP, 15 healthy controls, and three patients carrying MAPT variants. RESULTS: TDP43-SAA discriminated with 100% accuracy post mortem cases presenting or lacking TDP-43 neuropathology. TDP-43 seeding activity was detectable in the olfactory mucosa, and 82.4% of patients with FTLD-TDP tested positive, whereas 86.7% of controls tested negative (P < 0.001). Two out of three patients with MAPT mutations tested negative. In TDP43-SAA positive samples, cytoplasmatic deposits of phosphorylated TDP-43 in the olfactory neural cells were detected. DISCUSSION: TDP-43 aggregates can be detectable in olfactory mucosa, suggesting that TDP43-SAA might be useful for identifying and monitoring FTLD-TDP in living patients.


Sujet(s)
Démence frontotemporale , Dégénérescence lobaire frontotemporale , Humains , Démence frontotemporale/génétique , Dégénérescence lobaire frontotemporale/génétique , Dégénérescence lobaire frontotemporale/anatomopathologie , Protéines tau/génétique , Protéines tau/métabolisme , Lobe frontal/métabolisme , Neurones/métabolisme , Protéines de liaison à l'ADN/génétique , Protéines de liaison à l'ADN/métabolisme
17.
Cell ; 186(26): 5739-5750.e17, 2023 12 21.
Article de Anglais | MEDLINE | ID: mdl-38070510

RÉSUMÉ

Conscious perception is greatly diminished during sleep, but the underlying circuit mechanism is poorly understood. We show that cortical ignition-a brain process shown to be associated with conscious awareness in humans and non-human primates-is strongly suppressed during non-rapid-eye-movement (NREM) sleep in mice due to reduced cholinergic modulation and rapid inhibition of cortical responses. Brain-wide functional ultrasound imaging and cell-type-specific calcium imaging combined with optogenetics showed that activity propagation from visual to frontal cortex is markedly reduced during NREM sleep due to strong inhibition of frontal pyramidal neurons. Chemogenetic activation and inactivation of basal forebrain cholinergic neurons powerfully increased and decreased visual-to-frontal activity propagation, respectively. Furthermore, although multiple subtypes of dendrite-targeting GABAergic interneurons in the frontal cortex are more active during wakefulness, soma-targeting parvalbumin-expressing interneurons are more active during sleep. Chemogenetic manipulation of parvalbumin interneurons showed that sleep/wake-dependent cortical ignition is strongly modulated by perisomatic inhibition of pyramidal neurons.


Sujet(s)
Électroencéphalographie , Parvalbumines , Sommeil , Animaux , Souris , Neurones cholinergiques/physiologie , Lobe frontal/métabolisme , Parvalbumines/métabolisme , Sommeil/physiologie , Vigilance/physiologie
18.
Bull Exp Biol Med ; 175(6): 739-743, 2023 Oct.
Article de Anglais | MEDLINE | ID: mdl-37978148

RÉSUMÉ

The activity in the open field, short- and long-term memory in the novel object recognition test, and gait features were evaluated in 6- and 12-month-old male C57BL/6 mice. The levels of norepinephrine, dopamine, serotonin, and their metabolites were determined in the cerebellum and frontal cortex. In the observed age range, a decrease in locomotion speed, impairment of gait initiation and stability, and long-term memory deficit were revealed. In the cerebral cortex, reduced levels of dopamine and its metabolites and accelerated metabolism of all neurotransmitters under study were found. In the cerebellum, the content of all studied monoamines was elevated, while dopamine metabolism was decelerated. Analysis of correlations between the neurochemical and behavioral parameters showed that the mechanisms of compensation of brain functions during the early aging may be associated with an increase in activity of the monoaminergic systems in the cerebellum.


Sujet(s)
Dopamine , Norépinéphrine , Souris , Animaux , Mâle , Dopamine/métabolisme , Souris de lignée C57BL , Norépinéphrine/métabolisme , Cognition , Cervelet/métabolisme , Lobe frontal/métabolisme , Vieillissement , Encéphale/métabolisme , Monoamines biogènes/métabolisme
19.
Med J Malaysia ; 78(4): 476-483, 2023 07.
Article de Anglais | MEDLINE | ID: mdl-37518915

RÉSUMÉ

INTRODUCTION: Diabetes Mellitus (DM) is a chronic disease with many complications, one of which is diabetic encephalopathy which is characterised by memory dysfunction. Hyperglycaemia that occurs in DM will activate inflammatory pathways in neurons, including NF-κB pathway. Activation of this pathway produce proinflammatory agents such as MCP-1 and IL-6, which activate glial cells. Activation of glial cells is characterised by Glial Fibrillary Acid Protein (GFAP). Chlorogenic acid (CGA) has been reported to have anti-inflammatory effects and can improve memory function. This research aimed to determine the effect of CGA as anti-inflammation, its effect on memory function, mRNA expression of NF-κB, MCP-1, IL- 6, and GFAP of frontal lobe. MATERIALS AND METHODS: A total of 24 male rats were randomly divided into six groups: control, DM 1.5 month (DM1.5), DM 2 months (DM2) and the group with three different doses of CGA 12.5 (CGA1), 25 (CGA2), and 50 (CGA3) mg/KgBW. Frontal lobe tissue is taken for analysis of mRNA expression for NF-κB, MCP-1, IL-6, and GFAP using Reverse Transcriptase PCR (RT-PCR). Samples were also taken for histopathology preparation and stained by immunohistochemistry method using anti-GFAP antibodies to observe glial cell activation in frontal lobe tissue. RESULTS: The group that was given CGA at all doses have statistically significant better memory function, i.e. DM2 versus CGA1 (p = 0.036), CGA2 (p = 0.040), and CGA3 (p = 0.021). The result of mRNA expression in NF-κB was lower in the group given CGA, i.e. DM2 compared to CGA2 (p = 0.007). mRNA expression of MCP-1 was significantly lower in all CGA treatment groups compared to the non-CGA group (p = 0.000). IL-6 mRNA expression was lower than the group not given CGA, DM compared to CGA2 (p = 0.028). GFAP mRNA expression was lower than the group given CGA in DM, DM2 group compared to CGA1 (p = 0.04) and CGA3 (p = 0.004). CONCLUSION: Administration of CGA can improve memory function at all doses given, and can reduce brain inflammatory activity, especially in the CGA2 group.


Sujet(s)
Diabète , Facteur de transcription NF-kappa B , Rats , Mâle , Animaux , Facteur de transcription NF-kappa B/métabolisme , Acide chlorogénique/pharmacologie , Acide chlorogénique/usage thérapeutique , Interleukine-6 , Lobe frontal/métabolisme , ARN messager/métabolisme
20.
Acta Neuropathol Commun ; 11(1): 123, 2023 07 25.
Article de Anglais | MEDLINE | ID: mdl-37491342

RÉSUMÉ

Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with exposure to repetitive head impacts (RHI) and characterized by perivascular accumulations of hyperphosphorylated tau protein (p-tau) at the depths of the cortical sulci. Studies of living athletes exposed to RHI, including concussive and nonconcussive impacts, have shown increased blood-brain barrier permeability, reduced cerebral blood flow, and alterations in vasoreactivity. Blood-brain barrier abnormalities have also been reported in individuals neuropathologically diagnosed with CTE. To further investigate the three-dimensional microvascular changes in individuals diagnosed with CTE and controls, we used SHIELD tissue processing and passive delipidation to optically clear and label blocks of postmortem human dorsolateral frontal cortex. We used fluorescent confocal microscopy to quantitate vascular branch density and fraction volume. We compared the findings in 41 male brain donors, age at death 31-89 years, mean age 64 years, including 12 donors with low CTE (McKee stage I-II), 13 with high CTE (McKee stage III-IV) to 16 age- and sex-matched non-CTE controls (7 with RHI exposure and 9 with no RHI exposure). The density of vessel branches in the gray matter sulcus was significantly greater in CTE cases than in controls. The ratios of sulcus versus gyrus vessel branch density and fraction volume were also greater in CTE than in controls and significantly above one for the CTE group. Hyperphosphorylated tau pathology density correlated with gray matter sulcus fraction volume. These findings point towards increased vascular coverage and branching in the dorsolateral frontal cortex (DLF) sulci in CTE, that correlates with p-tau pathology.


Sujet(s)
Encéphalopathie traumatique chronique , Maladies neurodégénératives , Humains , Mâle , Adulte d'âge moyen , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Encéphalopathie traumatique chronique/anatomopathologie , Maladies neurodégénératives/anatomopathologie , Encéphale/anatomopathologie , Protéines tau/métabolisme , Lobe frontal/métabolisme , Athlètes
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...